loading page

Effect of Endoscopic Sinus Surgery on Clinical Outcomes in Cystic Fibrosis
  • +3
  • Anali Dadgostar,
  • Sepehr Nassiri,
  • Bradley Quon,
  • Jamil Manji,
  • Salahuddin Alsalihi,
  • Amin Javer
Anali Dadgostar
St Pauls Sinus Centre
Author Profile
Sepehr Nassiri
St Pauls Sinus Centre
Author Profile
Bradley Quon
The University of British Columbia Centre for Heart Lung Innovation
Author Profile
Jamil Manji
The University of Melbourne Faculty of Medicine Dentistry and Health Sciences
Author Profile
Salahuddin Alsalihi
St Pauls Sinus Centre
Author Profile
Amin Javer
St Pauls Sinus Centre
Author Profile

Abstract

Objectives: Chronic rhinosinusitis (CRS) is prevalent in the Cystic Fibrosis (CF) population. CRS exacerbations in CF are thought to contribute to pulmonary exacerbations. Literature regarding the impact of endoscopic sinus surgery (ESS) is inconclusive. This study examines rates of lung function decline and pulmonary exacerbation in CF patients who have undergone ESS. Design: Retrospective review of medical records. Setting: Academic Hospital. Participants: 40 adult CF patients. Main outcome measures: Rate of lung function decline (Forced Expiratory Volume1(FEV1) % predicted), number of pulmonary exacerbations (IV/oral antibiotic therapy +/- hospital admission) and total number days hospitalized 2 years post-operatively was collected. CRS patients undergoing ESS were matched to those without ESS by gender, age, and F508del genotype. Results: Forty patients (mean age 37.4, 60% male) were reviewed. No significant difference was found between the surgical group and controls in baseline FEV1(72.5% vs. 72.7%, p=0.98), 2-year pre-operative number of pulmonary exacerbations (3.05 vs. 1.65, p=0.10), or Lund-Mackay scores (12.25 vs. 11.55, p=0.71). No significant difference was found in 1-year (70.5% vs. 72.8%, p=0.84) or 2-year (70.4% vs. 72.6% p=0.80) post-operative FEV1 and 2-year post-operative pulmonary exacerbations (1.7 vs. 1.45, p=0.87). A significant increase was identified in total number days hospitalized post-operatively (4.85, p=0.02). In the surgical group, no significant difference was identified between preoperative and postoperative FEV1, 1 -year (-2.51%, p=0.32) and 2-years after ESS (-3.10%, p=0.51), postoperative rate of pulmonary exacerbations (-1.28, p=0.11), or in total number days hospitalized (3.74, p=0.14). Conclusions: In this study, ESS does not appear to significantly improve FEV1 or decrease the number of pulmonary exacerbations post-operatively.

Peer review status:UNDER REVIEW

13 May 2020Submitted to Clinical Otolaryngology
16 May 2020Submission Checks Completed
16 May 2020Assigned to Editor
17 May 2020Reviewer(s) Assigned
22 Jun 2020Review(s) Completed, Editorial Evaluation Pending
28 Jun 2020Editorial Decision: Revise Major
21 Sep 20201st Revision Received
24 Sep 2020Submission Checks Completed
24 Sep 2020Assigned to Editor
26 Sep 2020Reviewer(s) Assigned